USEUROPEAFRICAASIA 中文雙語Fran?ais
    China
    Home / China / China

    Drug watchdog to increase activities in China

    By Wang Hongyi in Shanghai | China Daily USA | Updated: 2014-05-23 11:52

     Drug watchdog to increase activities in China

    Brian Johnson, chairman of RX-360. Provided to China Daily

    The US-based RX-360, a global pharmaceutical industry consortium of volunteers protecting patient safety and enhancing supply-chain security, plans to increase its activities in China, which has become a major supplier for the global drug industry.

    The Washington-based nonprofit organization was established in 2009 to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain.

    "With globalization of distribution for both drug components and finished products, China has undoubtedly played an important role in the global pharmaceutical industry. The country has a large number of manufactures, supplying raw materials to the world," said Brian Johnson, chairman of RX-360, who is also the senior director of supply chain security at the drug company Pfizer. "How to ensure the security of sourcing and supply chain and increase the awareness in the country becomes very critical as with many problems that to date have yet to be resolved."

    The group's work in China will parallel what it has been doing in the US and Europe for several years, such as raising awareness of issues that have an impact on the security and integrity of pharmaceutical products and sharing best practices through education It will also promote the efficient use of joint and shared audit programs to continue to improve the transparency of supply channels.

    The group has also developed a series of tools and published white papers to help the industry and regulators address key areas of supply-chain security such as cargo theft, illegal product diversion, economically motivated adulteration, monitoring of drug shortages.

    "Our goal is to work with local industries and regulators to further our mission in China," said Johnson, adding that this is also a step for RX-360 to invite more participation by local suppliers throughout Asian countries.

    "Leading industry groups such as RX-360 will be very happy to share their expertise with local industries in combating security threats in our common supply chain. And I think these educational and best-practice sharing activities will benefit Chinese companies, especially those smaller ones," said William Pay, Greater China head of the global strategic sourcing office at Bayer Healthcare, which was a cofounding member of RX-360 consortium along with Pfizer, Takeda, Amgen , Eli Lily, Roche and others.

    The group also stressed the need for cracking down on online sales of counterfeited drugs, which has become increasingly rampant in China.

    In December last year, the Chinese government arrested more than 1,300 people involved in various counterfeit drugs sold on online.

    Earlier this month, China's Food and Drug Administration warned about authenticity and quality of overseas drugs sold online, and said 75 percent of overseas generic anti-cancer drugs supplied by online agents are fake and ineffective.

    Also this year, police from Central China's Henan province arrested 19 suspects for allegedly bogus medical devices, busting 13 marketing dens and seizing 48 medical devices originating from overseas waste.

    "The online sales of counterfeit drugs now are a big issue for the whole pharmaceutical industry in securing supply chain safety. More efforts should be given to this section, and meanwhile, how to carry out effective supervision work is also important," said Rory Budihandojo, director of the Asia-Pacific audit center of excellence at Boehringer Ingelheim China, also a member of the group.

    RX-360 was founded in the aftermath of the heparin scandal in 2008, when tainted raw heparin was found in finished products sold around the world, which led to the deaths of more than 100 Americans.

    Since then, RX-360 member companies in the pharmaceutical industry began to share their information of supply-chain security and also established white papers and guidance on preventing counterfeits and exposing other forms of pharmaceutical crimes.

    So far, the group has more than 80 members, including manufacturers, suppliers and industry associations. The group has set up an Asia Working Group run by Dr Zhijian Xiao, head of quality operations Asia Pacific of AstraZeneca.

    wanghongyi@chinadaily.com.cn

     

    Editor's picks
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    中文字幕av高清有码| 免费无码黄十八禁网站在线观看| 99精品人妻无码专区在线视频区| 日韩欧美中文亚洲高清在线 | 一本一道AV无码中文字幕| 亚洲国产精品无码专区| 成人精品一区二区三区中文字幕 | 亚洲欧洲美洲无码精品VA| 波多野结衣中文字幕久久| 免费无码AV一区二区| 日韩人妻无码一区二区三区久久| 亚洲日韩中文字幕日韩在线 | 中文人妻无码一区二区三区| 精品人无码一区二区三区| 亚洲欧洲自拍拍偷午夜色无码| 中文字幕免费视频一| 亚洲精品一级无码鲁丝片| gogo少妇无码肉肉视频| 国产在线无码一区二区三区视频| 在线高清无码A.| 成人无码网WWW在线观看| 亚洲精品一级无码中文字幕| 精品999久久久久久中文字幕| 亚洲成在人线在线播放无码| 精品久久久久久无码国产| 久久久无码人妻精品无码| 秋霞鲁丝片Av无码少妇| 日韩国产成人无码av毛片| 无码国产色欲XXXX视频| 亚洲精品无码午夜福利中文字幕 | 亚洲AV无码成H人在线观看| 2021无码最新国产在线观看| 国产爆乳无码视频在线观看| 黄桃AV无码免费一区二区三区| 日韩精品无码一区二区中文字幕| 无码欧精品亚洲日韩一区| 日韩免费人妻AV无码专区蜜桃| 久久久久久亚洲AV无码专区| 精品少妇无码AV无码专区| 久久精品无码免费不卡| 亚洲AV无码一区二三区|